SCHEMBL4466293

SCHEMBL4466293

N#Cc1c(NC2CCN(S(=O)(=O)c3ccccc3)C2)sc(C(=O)c2cc(-c3ccccc3)no2)c1N

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 11/20 0.44
CCR6 P51684 1/20 0.39
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
CHRM4 P08173 1/20 0.37
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
POLB P06746 1/20 0.36
PTPN1 P18031 1/20 0.36
MELK Q14680 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4473863 0.92 USP30 (0.45) USP30JAK1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL4485824 0.92 USP30 (0.45) USP30SMN1; SMN2ALDH1A1GAAMAPT
SCHEMBL4469460 0.88 USP30 (0.40) USP30CHRM4MEN1USP2HTT
SCHEMBL4477957 0.87 USP30 (0.47) USP30SMN1; SMN2ALDH1A1GAAMAPT
SCHEMBL4476832 0.86 USP30 (0.46) USP30MEN1HTTKMT2ASMN1; SMN2
SCHEMBL3824051 0.84 USP30 (0.44) USP30HTTKMT2ASMN1; SMN2ALDH1A1
SCHEMBL4467624 0.83 USP30 (0.43) USP30HTTSMN1; SMN2ALDH1A1GAA
SCHEMBL3831527 0.82 USP30 (0.51) USP30
SCHEMBL3818264 0.80 USP30 (0.41) USP30HTTKMT2ASMN1; SMN2ALDH1A1
SCHEMBL4467806 0.79 JAK3 (0.41) USP30JAK2JAK1CHRM4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A USP30 2232/4885CCR6 3813/4885JAK2 2951/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A USP30 2232/4885CCR6 3813/4885JAK2 2951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.